Ignite Creation Date:
2024-05-06 @ 12:55 PM
Last Modification Date:
2024-10-26 @ 1:06 PM
Study NCT ID:
NCT03884465
Status:
TERMINATED
Last Update Posted:
2021-09-13
First Post:
2019-03-04
Brief Title:
Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil
Sponsor:
Liquidia Technologies Inc
Organization:
Liquidia Technologies Inc
Study Overview
Official Title:
A Two Part Phase 2 Open-label Multi-Centre Dose Escalation Hemodynamic Study to Evaluate Dose-Response and Safety of Inhaled LIQ861 Treprostinil in Pulmonary Arterial Hypertension WHO Group 1 Subjects
Status:
TERMINATED
Status Verified Date:
2021-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
COVID
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Acute and chronic hemodynamic dose-response and safety evaluation of LIQ861 in PAH subjects
Detailed Description:
Data will be collected on acute and chronic hemodynamic response to inhaled dry powder treprostinil LIQ861 via right-heart catheterization Study subjects will contribute to the overall safety profile of LIQ861
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2018-003414-40 | EUDRACT_NUMBER | None | None |